Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Wynne

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b studySamit R Joshi, Ezequiel Cordova, Essack Mitha, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled AnalysisJoseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2020
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO StudyJean van Wyk, Faïza Ajana, Fiona Bisshop, et al.
Lancet (London, England)|November 14, 2018
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trialsPedro Cahn, Juan Sierra Madero, José Ramón Arribas, et al.
AIDS (London, England)|September 17, 2021
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infectionPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Omics : a Journal of Integrative Biology|January 25, 2014
Ready to put metadata on the post-2015 development agenda? Linking data publications to responsible innovation and science diplomacyVural Özdemir, Eugene Kolker, Peter J Hotez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2019
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical TrialsPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Environmental Sciences Europe|January 19, 2026
Scientists' warning: we must change paradigm for a revolution in toxicology and world food supplyGilles-Eric Seralini, Gérald Jungers, Arden Andersen, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b studySamit R Joshi, Ezequiel Cordova, Essack Mitha, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled AnalysisJoseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2020
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO StudyJean van Wyk, Faïza Ajana, Fiona Bisshop, et al.
Lancet (London, England)|November 14, 2018
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trialsPedro Cahn, Juan Sierra Madero, José Ramón Arribas, et al.
AIDS (London, England)|September 17, 2021
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infectionPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Omics : a Journal of Integrative Biology|January 25, 2014
Ready to put metadata on the post-2015 development agenda? Linking data publications to responsible innovation and science diplomacyVural Özdemir, Eugene Kolker, Peter J Hotez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2019
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical TrialsPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Environmental Sciences Europe|January 19, 2026
Scientists' warning: we must change paradigm for a revolution in toxicology and world food supplyGilles-Eric Seralini, Gérald Jungers, Arden Andersen, et al.
Pageof 8